ARGX vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARGX demonstrates strong financial health with a Piotroski F-Score of 6/9, indicating stable fundamentals despite a lack of Altman Z-Score. The company exhibits exceptional revenue growth (74.6% YoY) and a robust profit margin (30.42%), supported by a near-zero debt-to-equity ratio and high liquidity. While earnings declined YoY (-32%), this is likely due to one-time R&D investments and a prior-year anomaly, as evidenced by a massive 856.3% YoY EPS growth and consistent earnings surprises. The stock trades at a premium to its Graham Number ($228.72) and intrinsic value ($137.2), but this is justified by its high growth trajectory and strong analyst consensus. The 52-week price range suggests significant upside potential from current levels.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ARGX vs LLY: Head-to-Head Comparison
This page compares argenx SE (ARGX) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.